viewApricus Biosciences Inc

Apricus Biosciences Inc to prioritise Vitros erectile dysfunction drug

The decision follows an unsuccessful clinical trial for Apricus’ intended treatment for patients with hypogonadism and sexual dysfunction.

Vitros has already been approved in Europe and a US launch is targeted next year.

Apricus Biosciences Inc (NASDAQ:APRI) will prioritize Vitaros, its treatment for erectile dysfunction, and put the rest of its pipeline on the back-burner.

This strategic re-positioning will focus on clearing regulatory and commercialization hurdles so that it can achieve profitability via Vitaros.

It comes after news last month that a Phase 2b trial for its Fispemifen drug, a possible treatment for patients with hypogonadism and sexual dysfunction, failed to meet the primary endpoint (of ‘erectile function’) or the secondary endpoint (related to low libido).

Richard Pascoe, Apricus chief executive, described the recent fispemifene results as disappointing and said the priority now was on products that the company believe are most likely to generate ‘strategic value’.

He added: “Apricus’s development priority is now focused on Vitaros, both to accelerate commercialization outside of the US and to attempt to bring this novel erectile dysfunction therapy to patients in the US next year, with the goal of achieving profitability in 2017.”

The San Diego based drugs developer today said it will re-submit a new drugs application for Vitaros with the US Food & Drugs Administration in the third quarter of 2016, so that the drug can potentially be approved in the first half of next year.

Vitaros is already available in Europe and the Middle East and the company said it will aim to expand the drug’s availability in those territories with around ten new country launches through 2016 and the first half of 2017.

Apricus said it will discontinue all ongoing clinical activities relating to fispemifene for hypogonadism, and will deprioritise work on the drugs other potential indications.

The company also intends to significantly reduce operating costs. Staffing will reduce by 30%, including the executive team. It plans to cut overall operating expenses by 30% in 2016, and up to 60% next year.

Quick facts: Apricus Biosciences Inc

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Alkane Resources hits significant high-grade gold-copper mineralisation at Boda

Alkane Resources Limited's (ASX:ALK) Nic Earner speaks to Proactive soon after announcing they've intersected significant high-grade gold-copper mineralisation at the Boda Prospect within the Northern Molong Porphyry Project (NMPP) in NSW. Boda Prospect assay results have been concurrently...

13 hours, 28 minutes ago

2 min read